Kornimate/medical-research-clean huggingface dataset:
single nucleotide polymorphism (snp) in schizophrenia and schizophrenia spectrum disorders: a population association analysis with hong kong chinese

Conditions: Schizophrenia

Summary: gamma-aminobutyric acid (gaba) is the principal inhibitory neurotransmitter in the mammalian central nervous system. it is involved in a wide spectrum of physiological functions, from sleep and sedation to convulsions. a defect in neurotransmission involving gaba in schizophrenia was first propsed in early 1970s, based on neuropathologcial evidence, yet there is a lack of molecular genetic evidence. recently, we carried out a pilot study on a region of the gaba-a receptor β2 subunit gene on chromosome 5 and found significant association for single nucleotide polymorphisms (snps) in the gene sequence with occurrence of schizophrenia. the current proposal aims to validate this important finding and to conduct a thorough scanning of the complete gene sequences of the gaba-a receptor subunit genes in this chromosomal region, including the three major subunits α1, β2 and γ2. we shall collect samples from hong kong chinese subjects for a case-control study using haplotype maps and comparing the snp haplotype frequencies in the receptor genes, and hence examine whether these genes are in association with schizophrenia, or other schizophrenia-spectrum disorders, including alzheimer's disease presenting with psychotic symptoms. based on the observation that patients suffering from the catatonic subtype of schizophrenia respond particularly well to benzodiazepines, which bind specifically to gaba-a receptors, we shall also perform data analysis in terms of correlating snp association with schizophrenia subtypes. association of gaba-a receptor genes with schizophrenia would be a major step forward to determining whether these genes are susceptibility genes for schizophrenia, thereby paving the way to more effective diagnosis and treatment for this debilitating disease.


Eligibility criteria:
inclusion criteria: (for patients:) * diagnosis of schizophrenia under dsm-iv guidelines. exclusion criteria: (for controls:) * subjects who are known to have blood transmitted disease. * past or current alcohol and /or substance abuse. * past or current major medical and neurological conditions. (for patients:) * as for controls, excepr 3. "neurological conditions" does not include schizophrenia.

Keywords: schizophrenia schizophrenia spectrum disorder
heart health 4 moms trial to reduce cvd risk after preeclampsia

Conditions: Cardiovascular Disease; Preeclampsia; Hypertension; Post-partum Weight Retention

Summary: this study will compare two arms in a randomized clinical trial of cardiovascular risk prevention in women with a history of preeclampsia. the first arm will provide postpartum patients and their clinicians with the american heart association's (aha) class i lifestyle recommendations for women with a history of preeclampsia. the second arm will additionally receive access to a customized patient-informed online program with modules on how to achieve the aha recommendations for diet, activity and weight management.

the study team will work with patients via focus groups to develop a novel internet-based program to provide information and tools for cardiovascular disease (cvd) risk reduction for women who are at increased risk of cvd by virtue of their history of preeclampsia, a common complication of pregnancy. the american heart association has recently issued guidelines that physicians should include history of the hypertensive pregnancy disorder, preeclampsia, as a risk factor for cvd. indeed, research demonstrates that roughly 2 out of 3 women with a history of preeclampsia will die from cvd. this study will work with patients with prior preeclampsia and with the preeclampsia foundation, a patient- based organization, to create an online lifestyle modification program ( accessible by computer or smart phone) for women with recent preeclampsia to reduce cvd risk. the study is a randomized controlled trial to test the program's acceptability, use, and impact on diet, postpartum weight retention, physical activity, blood pressure, and patient knowledge and self-efficacy to improve health.

Eligibility criteria:
inclusion criteria: * within 5 years of a live birth complicated by preeclampsia as determined by medical chart review * age \>=18 * not pregnant * normotensive or prehypertensive * access to the internet via computer or mobile device * able to communicate in english or spanish at an 8th grade level. exclusion criteria: * type 1 or type 2 diabetes * currently pregnant * diagnosis of hypertension bp \>140/90 mm hg or on medications for treatment of hypertension

Keywords: preeclampsia cardiovascular disease health behaviors behavioral intervention web-based hypertension post-partum weight retention
comparing the efficacy and safety of nn1250 once daily when titrated using 2 different algorithms in insulin naïve subjects with type 2 diabetes mellitus

Conditions: Diabetes; Diabetes Mellitus, Type 2

Summary: this trial is conducted in europe and the united states of america (usa). the aim of this trial is to compare the efficacy and safety of nn1250 (insulin degludec (ideg)) once daily in insulin naïve subjects with type 2 diabetes mellitus when titrated using two different self-titration algorithms (dose individually adjusted) in combination with metformin.


Eligibility criteria:
inclusion criteria: * type 2 diabetes (diagnosed clinically) for at least 24 weeks prior to randomisation (visit 2) * current treatment: metformin monotherapy or metformin in any combination with 1 or 2 other oads including an insulin secretagogue (sulfonylurea or glinide), dipeptidyl peptidase iv (dpp-iv) inhibitors, alpha-glucosidase inhibitors, thiazolidinediones (tzds) all with unchanged dosing for at least 12 weeks prior to randomisation (visit 2)-metformin: alone or in combination (including fixed combination) must be at least 1000 mg daily * hba1c 7.0-10.0% (both inclusive) by central laboratory analysis * bmi (body mass index) no higher than 45.0 kg/m\^2 exclusion criteria: * treatment with glucagon-like peptide 1 (glp-1) receptor agonist within the last 12 weeks prior to visit 2 * suffer from a life threatening disease (e.g. cancer) * females of childbearing potential who are pregnant (as determined by central laboratory beta-human chorionic gonadotropin (beta-hcg), breast feeding or intend to become pregnant or are not using adequate contraceptive methods (adequate contraceptive methods as required by law or practise \[for germany, adequate contraceptive methods are: implants, injectables, combined oral contraceptives, hormonal iud, sexual abstinence or vasectomised partner\])
interstitial lung diseases in the veterans administration

Conditions: Interstitial Lung Disease

Summary: the primary objective of this research project is to describe the characteristics, diagnosis, management, and outcomes of patients with interstitial lung disease (ild) who received care at the veteran's administration veterans integrated service network (visn) 6 mid-atlantic health care network (visn6) (includes north carolina, virginia and west virginia) for up to 5 years.


Eligibility criteria:
inclusion criteria: * interstitial lung disease (ild) icd-9 code diagnosis 515.0 or 516.3 exclusion criteria: * inadequate documentation of patient receiving care for ild in the health records

Keywords: interstitial lung disease idiopathic pulmonary fibrosis electronic health records computed tomography mortality hospitalization acute care visits anti-inflammatory drug therapies
this study will collect clinical and patient reported experience data from participants requiring urine output management overnight in the home setting.

Conditions: Adult Nocturnal Enuresis; Urinary Incontinence (UI)

Summary: this post-market study will assess the performance of and user experience with the purewick™ system in a home setting. the study will also observe safety of the study device and collect information from participants about their quality of life before and after using the device.

approximately 150 women with nighttime urinary incontinence will take part in this prospective, open-label, randomized trial. participants will use one of two different study devices during the study to manage urine output at night: purewick™ system or the hollister® female urinary pouch external collection device. participant device assignment will be random. participants will use the assigned urine management device overnight while sleeping and will be followed for approximately 4 weeks.

Eligibility criteria:
inclusion criteria: 1. adult female participants greater than or equal to 18 years of age at the time of signing the informed consent. 2. currently use diapers or equivalent at night for urine output management. 3. willing to comply with all study procedures in this cip. 4. provision of signed and dated informed consent form. exclusion criteria: 1. has frequent episodes of bowel incontinence without a fecal management system in place; or 2. has moderate to heavy menstruation and cannot use a tampon or menstrual cup; or 3. has urinary tract, vaginal or other chronic infections, active genital herpes; or 4. has urinary retention; or 5. is agitated, combative, and/or uncooperative and may remove the external catheter or pouch; or 6. has any wound, open lesion or irritation on the genitalia, perineum, or sacrum; or 7. has any pre-existing neurological, psychiatric, or other condition that would confound quality of life assessment or would make it difficult to self-report on quality-of-life questionnaires in the opinion of the investigator; or 8. is known to be pregnant at time of enrollment (for women of childbearing age); or 9. any other condition that, in the opinion of the investigator, would preclude them from participating in the study.

Keywords: nighttime urinary incontinence quality of life sleep disturbance nqol promis purewick hollister females purewick flex female external catheter purewick urine collection system the hollister female urinary pouch bd becton, dickinson and company
effectiveness of fecal microbiota transplantation as add-on therapy in mild-to-moderate ulcerative colitis

Conditions: Ulcerative Colitis Chronic Mild; Inflammatory Bowel Diseases

Summary: ulcerative colitis (uc) is a chronic immune-mediated inflammatory bowel disease (ibd) that almost always affects the rectum and often extends to the more proximal colon. uc usually begins at a young age (15-30 years), most patients (\~ 85%) have a mild or moderate activity, characterized by periods of exacerbation and remission. considering the important pathogenetic role of gut dysbiosis, recently, as an additional method of treating uc, it is considered a modification of altered gut microbiota using various drug and non-drug methods. one such method is fecal microbiota transplantation (fmt), consisting of the simultaneous replacement of the gut microbiota of a sick recipient with fecal material from a healthy donor. even though so far the only officially approved indication for fmt is recurrent clostridium difficile infection, however, the effectiveness of fmt is currently being studied in the treatment of other gastrointestinal and non-gastrointestinal pathologies, including uc. to date, several controlled and uncontrolled studies have been conducted to study the effectiveness of fmt in uc, showing encouraging results. this study aimed to assess the clinical and microbiological efficacy, tolerability, and safety of fmt as add-on therapy to basic therapy, in patients with mild-to-moderate uc.


Eligibility criteria:
inclusion criteria: * age 18-60; * endoscopically and morphologically confirmed uc; * negative results of stool culture for the presence of pathogenic bacteria (shigella spp., salmonella spp., campylobacter spp., yersinia spp.) and toxin-producing clostridioides difficile; * partial mayo score of 4-6; * mayo endoscopic subscore ≥1; * fecal calprotectin \> 150 mcg/g * treatment with mesalazine at a daily dose of 3 g during the last 4 weeks exclusion criteria: * pregnancy, planning pregnancy or breastfeeding; * postponed operations on the abdominal cavity; * severe mental disorders, alcohol or drug abuse; * use of systemic corticosteroids, biological agents, and probiotics within 8 weeks before study * any condition or circumstance that would, in the opinion of the investigator, prevent completion of the study or interfere with analysis of study results.

Keywords: ulcerative colitis fecal microbiota transplantation gut microbiota dysbiosis inflammatory bowel disease
drug-coated balloon angioplasty for patients with symptomatic vertebral artery stenosis

Conditions: Vertebral Artery Stenosis

Summary: posterior circulation stroke accounts for 20% of ischemic stroke. a quarter occurs in patients with stenosis in the vertebral and/or basilar arteries. vertebral artery stenosis can be treated with stenting. however, in-stent restenosis rate have been reported as high as more than 30%, which may reduce the effect of stent therapy. drug-coated balloon has shown good results in controlling neointimal hyperplasia in the femoral and popliteal arteries.


Eligibility criteria:
inclusion criteria: * age 18 years or older * patients presenting with posterior circulation transient ischemic attack or nondisabling stroke in the previous 6 months * vertebral artery origin stenosis resulting from presumed atheromatous disease with stenosis ≥50% * lesion length of the stenosis \>5mm. * angioplasty can be performed within two weeks after randomization * female subjects of childbearing potential have a negative pregnancy test. * signed informed consent prior to entering study exclusion criteria: * potential cause of tia or minor stroke other than stenosis in a vertebral artery (e.g. atrial fibrillation) * life expectancy shorter than 2 years * vertebral artery stenosis caused by dissection * vertebral stenting felt to be technically impracticable * previous stenting in randomized artery * pre-morbid modified rankin scale score of greater than 3 * currently participating or previously participated in any investigational drug or device study within 6 months.

Keywords: vertebral artery stenosis drug-coated balloon angioplasty stenting
a study of ly3471851 in participants with psoriasis

Conditions: Psoriasis

Summary: the main purpose of this study is to learn more about the safety of ly3471851 when given by injection just under the skin to participants with psoriasis. the study will last up to 48 weeks and may include up to 23 visits to the study center.


Eligibility criteria:
inclusion criteria: * have a confirmed diagnosis of psoriasis for at least 6 months * have active psoriasis plaques according to study- specific criteria * be willing and able to undergo skin biopsies exclusion criteria: * have received certain topical medications for psoriasis within 14 days prior to baseline * have received certain systemic medications for psoriasis within 4 weeks prior to baseline * have received ly3471851 previously
loop band validation study

Conditions: COPD

Summary: the main purpose of this study is to assess the accuracy of a non-invasive wearable technology in the form of a wristband.

the main purpose of this study is to assess the accuracy of a non-invasive wearable technology in the form of a wristband. this wristband (loop band) uses optical sensors and spectrometry to measure and estimate vitals as well as a full blood gas panel; comparable to the standard method of an invasive arterial line and pressure transducer. the investigators aim to show equivalence of clinical physiologic outcome measurements with the loop band relative to current methods (i.e. arterial lines, etc.). in addition, this study aims to validate this wearable technology as a potential alternative to invasive measurements, to reduce complications, and improve accuracy in regards to patient monitoring.

Eligibility criteria:
inclusion criteria: * patient has capacity to consent for the study. * anesthetic plan for an arterial line for vital sign monitoring during their surgical procedure. exclusion criteria: * active atrial fibrillation * active c-difficile * amputation of the arm at the wrist or above * the investigator and/or clinical research nurse will conduct a visual inspection for attributes that may diminish device accuracy. these include but are not limited to: tattoos over the radial artery, burns or heavy scarring over the radial artery, fragile skin, any skin diseases affecting the wrist or arm, physician discretion-any condition deemed inappropriate that will preclude use of the device.

Keywords: copd copd exacerbation copd asthma copd bronchitis copd, severe early-onset
switch from premixed human insulin to biphasic insulin aspart in the netherlands

Conditions: Diabetes; Diabetes Mellitus, Type 2

Summary: this study is conducted in europe. the aim of this observational study is to observe and investigate the process of switching from premixed human insulin 30/70 (bhi 30) to biphasic insulin aspart 30/70 (biasp 30) in an outpatient setting.


Eligibility criteria:
inclusion criteria: * type 2 diabetic subjects treated with bhi 30
the impact of multimedia psychological support platform and acceptance and commitment therapy workshops of oncology nurses

Conditions: Oncology Nurse; Psychological Support; Acceptance and Commitment Therapy

Summary: based on the high levels of emotional distress, burnout, and turnover intentions among clinical oncology nursing staff, this study will provide a multimedia "mind-body support" line platform and act workshop courses as intervention measures for oncology nursing staff. the study aims to explore the effectiveness of these interventions in alleviating their psychological and physical distress, utilizing both qualitative and quantitative research methods to achieve the research objectives.


Eligibility criteria:
inclusion criteria: * currently working as an oncology nurse in a clinical setting exclusion criteria: * "unwilling or unable to participate in the full training course"
glycemic response in persons with type 2 diabetes

Conditions: Diabetes Mellitus, Type 2

Summary: this will be a randomized crossover design with nutrition supplement interventions.

this will be a randomized crossover design with three oral nutrition supplement interventions. the subjects will be randomized to one of three interventions on three separate study days, one week apart.

Eligibility criteria:
inclusion criteria: * age 20-75 years * type 2 diabetes controlled with diet or diet and metformin (glucophage) * hemoglobin a1c less than 9.0% * fasting blood glucose less than 180 mg * hematocrit levels within normal limits * having obtained his/her informed consent exclusion criteria: * abnormal thyroid function * creatinine \>2.0 mg/dl * potassium \<3.5 meq/l * gastrointestinal disease: ulcer, gastritis, diarrhea, gastroparesis, vomiting * currently unstable diabetes or under treatment for cancer, heart disease, renal disease * unable to give informed consent or follow instructions * current insulin therapy or insulin therapy within the past month * patient who are pregnant * allergies to milk, soy or any component of the test product * patient who in the investigators assessment cannot be expected to comply with treatment * currently participating or having participated in another clinical trial * patients with anemia
apex study: effects of allopurinol on coronary and peripheral endothelial function in patients with cardiac syndrome x

Conditions: Syndrome X

Summary: morbidity of patients with cardiac syndrome x (typical anginal-like chest pain and normal coronary arteriograms) is high with continuing episodes of chest pain and frequent hospital readmissions. management of this syndrome represents a major challenge to the treating physician. evidence for the important role of endothelial dysfunction and oxidative stress in the pathogenesis of cardiac syndrome x has been recently strengthened by the finding that basal superoxide production predicts future cardiovascular events in this patient group. the investigators have recently shown that high-dose allopurinol abolishes vascular oxidative stress and improves endothelial function in patients with chronic heart failure, which makes allopurinol a prime candidate to reduce oxidative stress in syndrome x. the hypothesis to be tested in this study is whether allopurinol offers dual benefits of improving vascular function and reducing myocardial ischaemia in patients with cardiac syndrome x. this study may discover a novel way to improve endothelial function and anginal symptoms which are often debilitating in these patients.


Eligibility criteria:
inclusion criteria: * typical history of angina * positive exercise treadmill test and normal coronary angiogram exclusion criteria: * significant valvular heart disease or left ventricular hypertrophy * age \<18 years

Keywords: cardiac syndrome x endothelial function
coupler-based hearing-aid fitting approach for experienced users

Conditions: Hearing Loss

Summary: the overall aim of the study is to compare the verification accuracy and hearing-aid outcomes between the traditional, fitting approach where the patient is present during the visit and a coupler-based fitting approach where the patient is not present and mailed their hearing aids. if the coupler-based fitting protocol tested in this study as effective as the traditional fitting protocol, then patients receiving replacement hearing aids may circumvent a face-to-face visit.

this study will incorporate a verification technique that simulates the patient's actual ear during probe microphone verification measurements, called real-ear to coupler difference (recd). because the patient's ear is not used during the recd measurement, but rather simulated, the patient would not need to be present during the recd verification. this recd hearing aid verification can occur in the clinic after which the hearing aids will be mailed to the patient. this study will compare the fitting accuracy and outcomes between the two approaches.

Eligibility criteria:
inclusion criteria: * no more than a moderate sensorineural hearing loss (defined as \< 60 db hl pure-tone average at 500, 1000, and 2000 hz au) * experienced bte hearing-aid users who are obtaining replacement va-issued bte hearing aids coupled to a custom earmold that is simply an upgrade in model with the same style earmold * ability to read and write in english as determined by reading a few sentences from the consent document aloud so that self-report measures can be completed exclusion criteria: * outer or middle ear pathology as determined by otoscopy, immittance, and/or audiometric testing (e.g., conductive or mixed losses) * lack of phone or non-use of the phone as the participants will be required to conduct a telephone interview after they obtain their replacement hearing aids * unwilling or unable to be mailed hearing aids * co-morbid condition that would preclude their participation as determined by a chart review

Keywords: hearing loss hearing aids outcome assessment